Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
2026. nov. 11.· PHASE1 · RECRUITING· CTGOV
Publikáció
The PDE4 inhibitor tanimilast (CHF6001) activates CFTR function in native and in F508del-expressing airway epithelial cells.
2026. nov. 5.· European journal of pharmacology· PUBMED
Vizsgálat
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
2026. okt. 30.· PHASE3 · RECRUITING· CTGOV
Publikáció
The emerging role of PDE4 inhibitors for the treatment of pulmonary fibrosis.
2026. szept. 28.· Expert review of clinical pharmacology· PUBMED
Publikáció
Structural modification of imperatorin affords promising dual AhR/PDE4 modulators for anti-inflammatory therapy.
2026. aug. 5.· European journal of medicinal chemistry· PUBMED
Publikáció
A Comprehensive Review of Phosphodiesterases 4 (PDE4) Inhibitors in Clinical Trials.
2026. júl. 23.· Current pharmaceutical design· PUBMED
Publikáció
Novel Resveratrol Derivatives as Dual PDE4 Inhibitors and Free Radical Scavengers: Rational Design, Synthesis, and Biological Evaluation.
2026. júl. 20.· Antioxidants (Basel, Switzerland)· PUBMED
Publikáció
Precision Modulation of the PDE4 Pathway: The Emerging Role of Nerandomilast in Pulmonary Fibrosis.
2026. júl. 16.· The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians· PUBMED
Publikáció
Safety, pharmacokinetics and pharmacodynamics of TQC3721, an innovative, dual PDE3 and PDE4 inhibitor, in healthy subjects and patients with chronic obstructive pulmonary disease: Randomised, double-blind, placebo-controlled phase I and IIa clinical trials.
2026. júl. 14.· British journal of pharmacology· PUBMED
Vizsgálat
This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling
2026. jún. 30.· PHASE2_PHASE3 · NOT_YET_RECRUITING· CTGOV
Publikáció
Efficacy and safety of PDE4 inhibitor monotherapy in adult patients with atopic dermatitis: a systematic review and meta-analysis.
2026. jún. 19.· Postepy dermatologii i alergologii· PUBMED
Publikáció
Comprehensive Pharmacokinetics of the Marine-Derived PDE4 Inhibitor LY104 and Its Major Metabolite M1 in Rats: A Validated LC-MS/MS Method with Sex Comparison, Multiple-Dose, Protein Binding, Metabolic Stability, and Excretion Studies.
2026. jún. 15.· Marine drugs· PUBMED
Publikáció
Pharmacokinetics, Safety and Tolerability of HPP737, a Novel PDE4 Inhibitor, in Healthy Chinese Participants: Phase I Study.
2026. máj. 19.· Drug design, development and therapy· PUBMED
Publikáció
Natural PDE4 inhibitors from plants: A comprehensive review of discovery, structure-activity relationships, and clinical translation potential.
2026. máj. 19.· European journal of medicinal chemistry· PUBMED
Publikáció
LS21013A-06, a PDE4 inhibitor, preserves blood-brain barrier integrity in experimental ischemic stroke models through PKA-dependent modulation of LECT2.
2026. ápr. 25.· European journal of pharmacology· PUBMED
Publikáció
The effects of the PDE4 inhibitor roflumilast on cognitive performance after a cerebrovascular accident: a double-blind randomized placebo-controlled trial with an open label extension (ROSTMEMA).
2026. ápr. 24.· Journal of psychopharmacology (Oxford, England)· PUBMED
Publikáció
Dual targeting of MEK1 and PDE4 by Total lignans from flower buds of Magnolia biondii Pamp. Alleviates atopic dermatitis.
2026. ápr. 22.· Fitoterapia· PUBMED
Vizsgálat
Crisaborole vs Fluticasone Propionate in Mild to Moderate Atopic Dermatitis
2026. ápr. 17.· NA · COMPLETED· CTGOV
Publikáció
Variecolactone, a Natural PDE4 Inhibitor from Marine-Derived Talaromyces sp. ZSD-1, Alleviates Amyloid-β Accumulation and mtDNA Dyshomeostasis via cAMP-PKA-CREB Signaling Pathway.
2026. ápr. 12.· Biomolecules· PUBMED
Publikáció
SIK1 drives lipid-induced insulin resistance in skeletal muscle by linking TGFβ1-Smad2/3 activation to PDE4-cAMP dysregulation.
2026. márc. 17.· Molecular and cellular endocrinology· PUBMED
Publikáció
PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.
2026. márc. 15.· Expert opinion on pharmacotherapy· PUBMED
Publikáció
Enhancement of memory network activity in schizophrenia patients by phosphodiesterase-4 (PDE4) inhibitor, roflumilast: A pilot study.
2026. márc. 11.· Journal of psychopharmacology (Oxford, England)· PUBMED
Publikáció
PDE4 inhibitor DC591017 ameliorates pulmonary fibrosis through modulating fibroblasts-epithelial cells-alternatively activated macrophages crosstalk.
2026. febr. 28.· European journal of pharmacology· PUBMED
Publikáció
Discovery of Marine-Inspired Guanidine-Based PDE4 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.
2026. febr. 25.· Marine drugs· PUBMED
Publikáció
Discovery of Potent PDE4 Inhibitors with 3(2H)-Pyridazinone Scaffold: Synthesis, In Silico Studies and In Vitro/Vivo Evaluation.
2026. febr. 17.· Molecules (Basel, Switzerland)· PUBMED
Publikáció
Design, synthesis and exploration of cyclic imides as PDE4 inhibitors in psoriasis.
2026. febr. 13.· RSC medicinal chemistry· PUBMED
Preprint
PDE4 Inhibitor Apremilast Rebalances Inflammatory Responses to Pseudomonas aeruginosa Infection in CF Rats.
2026. febr. 10.· bioRxiv : the preprint server for biology· PUBMED
Publikáció
Discovery, Synthesis, and Biological Evaluation of Novel Quinoline-Based PDE4 Inhibitors with Potent Anti-Chronic Obstructive Pulmonary Disease Activity.
2026. febr. 5.· Journal of medicinal chemistry· PUBMED
Publikáció
Discovery of Novel Natural Product-Based PDE4 Inhibitors for Ischemic Stroke Treatment without Emetogenicity at Ultra-High Doses.
2026. jan. 30.· Journal of medicinal chemistry· PUBMED
Publikáció
Roflupram Reduces 6-OHDA-Induced Cellular Damage in SH-SY5Y Cells by Inhibiting PDE4.
2026. jan. 23.· Journal of integrative neuroscience· PUBMED